Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2004. The report primarily details changes in directors' share interests and provides six-monthly returns (December 30, 2003, to June 30, 2004) regarding various employee share option and savings schemes.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data present relates to share transactions:
- Total Shares in Issue: 5,933,804,359 (as of the end of the reporting period).
- Share Purchase Price (Director): GBP 10.88 per Ordinary Share (July 9, 2004).
- Share Purchase Price (Trust Reinvestment): GBP 10.82 per Ordinary Share (July 1, 2004 dividend reinvestment).
Material Changes
The filing reports specific changes in share ownership and scheme allocations:
- Director Acquisition: Mr. J.D. Coombe acquired 22 Ordinary Shares (11 personal, 11 company match) under the ShareReward Plan.
- Trust Activity: The SmithKline Beecham Employee Benefit Trust purchased 1,287 shares for the Bonus Investment Plan and 9,075 shares for the Annual Investment Plan following dividend reinvestment. Transfers of 1,334 and 1,651 shares were also noted.
- Share Issuances: Significant shares were issued under various schemes during the six-month period, including 238,360 under the ADS Share Option Plan, 506,959 under the Glaxo Group Limited scheme, and 731,120 under the SmithKline Beecham Unapproved ADS plan.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. The document is strictly a regulatory disclosure of share ownership changes and scheme administration.
Investor Verification Checklist
- Verify the total number of shares in issue (5,933,804,359) against the company's latest capitalization table.
- Confirm the impact of the 22 shares acquired by Director J.D. Coombe on total insider ownership.
- Review the specific terms of the "ShareReward Plan" and "Employee Benefit Trust" to understand the dilution mechanics of the reported share issuances.
- Note that this filing contains no operational or financial performance data; refer to the most recent Form 20-F or interim results for financial metrics.